How should I assess and manage a mild versus severe reaction after vaccination?

Assessment and Management of Vaccine Reactions

Screen every patient before vaccination for contraindications and precautions, observe for 15-20 minutes post-vaccination, and immediately treat severe allergic reactions with intramuscular epinephrine while maintaining airway support. 1

Initial Assessment Framework

Timing Classification

Vaccine reactions are categorized by onset time, which guides both diagnosis and management 2:

• Immediate reactions: Occur within 4 hours of vaccination, potentially IgE-mediated, require allergy workup 2
• Non-immediate reactions: Occur after 4 hours, generally not IgE-mediated 2
• Critical window: 63% of syncopal episodes occur within 5 minutes, and 89% within 15 minutes of vaccination 1

Severity Classification

Mild/Local Reactions (most common) 1:

• Injection site pain, swelling, redness
• Low-grade fever (<102°F in adults)
• Mild headache, fatigue, myalgia
• Regional lymphadenopathy
• Management: Observation and supportive care only; no allergy workup needed 3, 2

Moderate Reactions 4:

• Fever >102°F
• Extensive local swelling beyond the joint
• Moderate systemic symptoms interfering with daily activities
• Management: Symptomatic treatment; document for future vaccination decisions

Severe Reactions (rare) 1:

• Anaphylaxis: Flushing, facial edema, urticaria, mouth/throat swelling, wheezing, difficulty breathing, cardiovascular collapse
• Syncope with injury: Skull fractures, cerebral bleeding
• Encephalopathy: Altered consciousness, prolonged seizures (specific to pertussis-containing vaccines) 4

Immediate Management of Severe Reactions

Anaphylaxis Protocol 1

Immediate actions (within minutes):

1. Place patient in recumbent position with legs elevated 1
2. Administer aqueous epinephrine 1:1000 intramuscularly immediately 1
   • Can be repeated within 10-20 minutes if needed 1
3. Maintain airway and administer oxygen 1
4. Diphenhydramine hydrochloride may shorten reaction but has little immediate effect 1
5. Arrange immediate transfer to emergency facility for further evaluation 1

Critical preparation requirements 1:

• All vaccine providers must have epinephrine and airway equipment immediately available 1
• All providers must be certified in cardiopulmonary resuscitation 1
• Office emergency plan must be established and familiar to all staff 1

Syncope Management 1

• Observe patient until symptoms completely resolve 1
• Most common in adolescents and young adults aged 10-18 years 1
• Can result in serious injury including skull fractures and cerebral bleeding 1
• Prevention: Observe all patients for 15-20 minutes post-vaccination when possible 1

Post-Reaction Evaluation and Future Vaccination

Contraindications for Future Doses 4

Absolute contraindications (do not revaccinate with same vaccine):

• Severe allergic reaction (anaphylaxis) to previous dose or vaccine component 4
• Encephalopathy within 7 days of pertussis-containing vaccine administration 4

Precautions Requiring Risk-Benefit Assessment 4

• Guillain-Barré syndrome within 6 weeks after tetanus toxoid-containing vaccine 4
• History of Arthus-type hypersensitivity after tetanus/diphtheria toxoid; defer until ≥10 years since last dose 4
• Moderate or severe acute illness with or without fever 4

Allergy Evaluation Pathway 5, 2, 6

Key principle: Most suspected vaccine allergies are not confirmed—up to 85% of cases referred for allergy evaluation can continue vaccination with the same formulation 5

When to refer for allergy workup 2:

• Immediate reactions (<4 hours) suggesting IgE-mediated hypersensitivity 2
• Known allergy to specific vaccine components (gelatin, yeast, latex, antibiotics) 2
• Not required: Previous egg allergy is not a contraindication to egg-based vaccines, including influenza 6

Evaluation by allergist/immunologist 5:

• Select patients at true risk of allergic reactions 5
• Perform appropriate diagnostic procedures 5
• Determine safe immunization strategy 5
• Most patients can receive subsequent doses safely 6

Special Considerations

Component Allergies 7, 6

• Egg allergy: No longer requires special protocols or skin testing for measles-containing or influenza vaccines 7, 6
• Gelatin: Rare cause of anaphylaxis; requires evaluation if known sensitivity 7, 2
• Latex: Consult package insert for latex content 4
• Antibiotics, yeast: Require allergy workup before vaccine administration 2

COVID-19 mRNA Vaccine Reactions 8, 9

• First-dose reactions: Most individuals with reported allergic reactions tolerate second dose safely (99.84%) 9
• Severe first-dose reactions: Only 4.94% experience second severe reaction 9
• Polyethylene glycol (PEG) skin testing: Limited predictive value; positive tests do not preclude safe revaccination 8
• Recommendation: Revaccinate in supervised setting equipped to manage severe reactions 9

Documentation Requirements

Record for every vaccination 1:

• Vaccine type, manufacturer, lot number
• Date and time of administration
• Site and route of administration
• Any immediate reactions and their management
• Patient education provided regarding delayed reactions

Common Pitfalls to Avoid

1. Do not withhold vaccines based on minor local reactions 1, 2
2. Do not label patients as "vaccine allergic" without proper allergy evaluation—most can be safely revaccinated 5, 6
3. Do not use reduced or split doses—inadequate protection results; revaccinate with full dose 1
4. Do not confuse vasovagal syncope with anaphylaxis—different management and implications 1
5. Do not delay vaccination for minor febrile illness—mild upper respiratory infections are not contraindications 7
6. Do not require routine physical examination or temperature measurement before vaccinating apparently healthy individuals 7